Regulation of B cell function in demyelinating disease by N-glycan branching
N-聚糖分支调节脱髓鞘疾病中的 B 细胞功能
基本信息
- 批准号:10311524
- 负责人:
- 金额:$ 50.05万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2019
- 资助国家:美国
- 起止时间:2019-01-14 至 2023-12-31
- 项目状态:已结题
- 来源:
- 关键词:Anti-Inflammatory AgentsAntibody FormationAntigen-Presenting CellsAntigensAutoimmune DiseasesAutoimmunityB cell therapyB-Cell Antigen ReceptorB-LymphocytesBindingBinding ProteinsCD19 geneCTLA4 geneCell CountCell Differentiation processCell physiologyCell surfaceCellsCerebrospinal FluidDataDemyelinating DiseasesDemyelinationsDiseaseEndocytosisEnvironmentFamily memberGalactose Binding LectinGeneticGenetic VariationGrowth InhibitorsHumanHuman GeneticsHyperactivityImmuneImmune systemIndividualInflammatoryInterleukin-10LigandsMediatingMembrane GlycoproteinsMetabolicMixed Lymphocyte Culture TestMonoclonal Antibody CD20Multiple SclerosisMusNerve DegenerationPL/J MousePLCgamma2Pathway interactionsPhenotypePlasma CellsPlayPolysaccharidesPredispositionProductionProtein GlycosylationProteinsPublishingReceptor SignalingRegulationRoleSignal TransductionSurfaceT cell responseT-Cell ReceptorT-LymphocyteTLR2 geneTLR4 geneTNF geneTestingTh1 CellsTh2 CellsToll-like receptorsWorkadaptive immune responseanti-CD20axon injuryimmune functionimmunological synapselink proteinmultiple sclerosis patientneuron lossreceptorreceptor functionresponsesugarvirtual
项目摘要
Abstract
Our published work has revealed that deficiencies in Asn (N)-linked protein glycosylation
reduce inflammatory demyelination in mice and are associated with Multiple Sclerosis (MS). Deficiency
in the branching of N-glycan's attached to proteins, either induced experimentally in mice or via natural genetic
variation in humans, promotes T-cell mediated inflammatory demyelination and neurodegeneration. For
example, branching deficiency induces a spontaneous and slowly progressive MS-like disease in PL/J mice,
characterized by inflammatory demyelination, axonal damage and neuronal death. Mechanistically, the
branching and number of N-glycans per protein molecule cooperate to regulate binding to galectins, a 14-
member family of sugar binding proteins. Galectin binding to cell surface glycoproteins, via their attached N-
glycans, forms a macro-molecular lattice at the cell surface that controls the distribution, clustering and
endocytosis of surface glycoproteins in a coordinated and predictable manner. N-glycan branching markedly
inhibits T cell activity in mice and humans by reducing T cell receptor clustering/signaling at the immune
synapse, promoting surface retention of the growth inhibitor CTLA-4 and inhibiting differentiation into pro-
inflammatory TH1 and TH17 cells while promoting anti-inflammatory iTreg and TH2 cell differentiation. Although
these T cell phenotypes are important regulators of inflammatory demyelination, it has become increasing clear
that B cells also play a critical role in MS. This is best exemplified by the potent activity of B cell depleting
therapies in MS, such as the anti-CD20 monoclonal antibody ocrelizumab. B cells are unique in the immune
system by having both innate and adaptive immune activity; the former exemplified by activation via Toll-like
receptors (TLR) and antigen-presenting cell (APC) functions that trigger T cell responses. The mechanism of
action of ocrelizumab appears to primarily result from reduced innate immune activity rather than altering
antibody production, as ocrelizumab reduces T cell number but not antibody or plasma cell levels in the
cerebral spinal fluid of treated MS patients. Here we test the hypothesis that N-glycan branching serves as
a critical negative regulator of pro-inflammatory innate immune activity in B cells to suppress pro-
inflammatory T cell responses and inflammatory demyelination. To evaluate this hypothesis, the following
Aims are proposed. Aim 1 examines regulation of TLR4 and TLR2 responses by N-glycan branching in B cells.
Aim 2 examines regulation of B cell receptor signaling by N-glycan branching. Aim 3 examines whether N-
glycan branching in B cells suppresses inflammatory demyelination. Positive results will identify N-glycan
branching as a major contributor to B cell mediated regulation of inflammatory demyelination and has
implications for understanding the mechanism of action of B cell depleting therapies in MS.
摘要
我们已发表的工作表明,Asn(N)连接蛋白糖基化的缺陷
减少小鼠的炎性脱髓鞘,并与多发性硬化症(MS)有关。缺乏
在连接到蛋白质的N-聚糖的分支中,无论是在小鼠中实验诱导还是通过天然遗传
人类的变异,促进T细胞介导的炎症性脱髓鞘和神经退行性变。为
例如,分支缺乏会诱导PL/J小鼠自发且缓慢进展的MS样疾病,
其特征在于炎性脱髓鞘、轴突损伤和神经元死亡。机械地,
每个蛋白质分子的N-聚糖的分支和数量协同调节与半乳糖凝集素的结合,半乳糖凝集素是一种14-
糖结合蛋白家族成员。半乳糖凝集素结合细胞表面糖蛋白,通过其连接的N-
聚糖,在细胞表面形成大分子晶格,控制分布,聚集和
细胞以协调和可预测的方式内吞表面糖蛋白。N-聚糖分支显著
通过减少免疫系统中的T细胞受体聚集/信号传导来抑制小鼠和人类中的T细胞活性
突触,促进生长抑制剂CTLA-4的表面保留,并抑制分化为前
在一些实施方案中,本发明的组合物可抑制炎性TH 1和TH 17细胞,同时促进抗炎性iTreg和TH 2细胞分化。虽然
这些T细胞表型是炎性脱髓鞘的重要调节因子,
B细胞也在MS中起关键作用。这最好地由B细胞消耗的有效活性来例证。
MS治疗,如抗CD 20单克隆抗体ocrelizumab。B细胞在免疫系统中是独一无二的。
系统具有先天性和适应性免疫活性;前者的例子是通过Toll样激活
受体(TLR)和抗原呈递细胞(APC)的功能,触发T细胞反应。的机理
ocrelizumab的作用似乎主要是由于先天性免疫活性降低而不是改变
抗体产生,因为ocrelizumab减少T细胞数量,但不减少抗体或浆细胞水平。
治疗的MS患者的脑脊液。在这里,我们测试的假设,N-聚糖分支作为
在B细胞中促炎性先天免疫活性的关键负调节剂,以抑制促炎性先天免疫活性。
炎性T细胞反应和炎性脱髓鞘。为了评估这一假设,
提出了目标。目的1检测B细胞中N-聚糖分支对TLR 4和TLR 2应答的调节。
目的2研究N-聚糖分支对B细胞受体信号传导的调节。目标3考察N-
B细胞中的聚糖分支抑制炎性脱髓鞘。阳性结果将鉴别N-聚糖
分支作为B细胞介导的炎症性脱髓鞘调节的主要贡献者,
对理解MS中B细胞耗竭疗法的作用机制的意义。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
MICHAEL DEMETRIOU其他文献
MICHAEL DEMETRIOU的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('MICHAEL DEMETRIOU', 18)}}的其他基金
Extended half-life GlyTR1 combined with checkpoint blockade for Cancer Immunotherapy
延长半衰期的 GlyTR1 与检查点阻断相结合用于癌症免疫治疗
- 批准号:
10766646 - 财政年份:2023
- 资助金额:
$ 50.05万 - 项目类别:
Regulation of B cell function in demyelinating disease by N-glycan branching
N-聚糖分支调节脱髓鞘疾病中的 B 细胞功能
- 批准号:
10535482 - 财政年份:2019
- 资助金额:
$ 50.05万 - 项目类别:
Mechanisms of human immune modulation by oral N-acetylglucosamine
口服N-乙酰氨基葡萄糖调节人体免疫的机制
- 批准号:
9272357 - 财政年份:2014
- 资助金额:
$ 50.05万 - 项目类别:
Mechanisms of human immune modulation by oral N-acetylglucosamine
口服N-乙酰氨基葡萄糖调节人体免疫的机制
- 批准号:
8851521 - 财政年份:2014
- 资助金额:
$ 50.05万 - 项目类别:
相似海外基金
Characterization of Naturally Occurring Anti-Blood Group Antibody Formation
天然存在的抗血型抗体形成的表征
- 批准号:
9981001 - 财政年份:2017
- 资助金额:
$ 50.05万 - 项目类别:
Characterization of Naturally Occurring Anti-Blood Group Antibody Formation
天然存在的抗血型抗体形成的表征
- 批准号:
9751102 - 财政年份:2017
- 资助金额:
$ 50.05万 - 项目类别:
Characterization of Naturally Occurring Anti-Blood Group Antibody Formation
天然存在的抗血型抗体形成的表征
- 批准号:
9397073 - 财政年份:2017
- 资助金额:
$ 50.05万 - 项目类别:
Characterization of Naturally Occurring Anti-Blood Group Antibody Formation
天然存在的抗血型抗体形成的表征
- 批准号:
10223410 - 财政年份:2017
- 资助金额:
$ 50.05万 - 项目类别:
PREVENTING NEUTRALIZING ANTIBODY FORMATION IN MS PATIENTS WITH SC IFN-BETA (REBI
使用 SC IFN-β (REBI) 预防 MS 患者中和抗体形成
- 批准号:
7951676 - 财政年份:2008
- 资助金额:
$ 50.05万 - 项目类别:
PREVENTING NEUTRALIZING ANTIBODY FORMATION IN MS PATIENTS WITH SC IFN-β-AL
预防 SC IFN- 多发性硬化症患者中和抗体的形成
- 批准号:
7606036 - 财政年份:2006
- 资助金额:
$ 50.05万 - 项目类别:
IMMUNOLOGIC MECHANISM OF INHIBITOR ANTIBODY FORMATION IN HEMOPHILIA
血友病抑制剂抗体形成的免疫学机制
- 批准号:
7375053 - 财政年份:2005
- 资助金额:
$ 50.05万 - 项目类别:
IMMUNOLOGIC MECHANISM OF INHIBITOR ANTIBODY FORMATION IN HEMOPHILIA
血友病抑制剂抗体形成的免疫学机制
- 批准号:
7201220 - 财政年份:2004
- 资助金额:
$ 50.05万 - 项目类别:
Immunologic Mechanism of Inhibitor Antibody Formation in Hemophilia
血友病抑制剂抗体形成的免疫学机制
- 批准号:
6980810 - 财政年份:2003
- 资助金额:
$ 50.05万 - 项目类别:
INHIBITOR ANTIBODY FORMATION IN HEMOPHILIA AND VON WILLEBRAND'S DISEASE
血友病和冯·维勒布兰德病中的抑制剂抗体形成
- 批准号:
6419444 - 财政年份:2000
- 资助金额:
$ 50.05万 - 项目类别: